Heming Li

6PUBLICATIONS
9CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 27, 2026
Repurposed Acarbose Targets Nidogen-1 to Remodel the Tumor Stroma and Suppress Portal Vein Tumor Thrombus in Hepatocellular Carcinoma.

Tao Han, Lujun Chen, Ning Liu

|Sep 15, 2025
The 3PM transformation potential of minimal residual disease in solid tumor management: a bibliometric analysis and review.

Yining Chen, Xin Li, Suya Zhao

|Jun 23, 2025
A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer.

Jingqi Sun, Junli Hao, Xin Li

|Jul 31, 2024
FGL1: a novel biomarker and target for non-small cell lung cancer, promoting tumor progression and metastasis through KDM4A/STAT3 transcription mechanism.

Tian Yao Liu, Jin Shan Yan, Xin Li

|Apr 01, 2022
RBMS1 promotes gastric cancer metastasis through autocrine IL-6/JAK2/STAT3 signaling.

Mengyuan Liu, Heming Li, Huijing Zhang

|Sep 16, 2021
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.

Wenjing Qian, Mingfang Zhao, Ruoyu Wang

Pageof 1

Frequent Collaborators

3 joint publications

Mingfang Zhao

2 joint publications

Lu Xu

2 joint publications

Tao Han

1 joint publications

Jingqi Sun